Sab Biotherapeutics, Inc.7月29日成交额为51.70万美元

市场透视07-30

美东时间2025年7月29日，Sab Biotherapeutics, Inc.（SABS.US）成交额为51.70万美元，成交额较昨日增加4.62%，当日成交量为21.85万股。Sab Biotherapeutics, Inc.（SABS.US）于2025年7月29日跌10.47%，报2.27美元，该股过去5个交易日跌13.22%，年初至今跌40.24%，过去60日涨33.24%。|近5个交易日...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555097653?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-30 13:59","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2555097653","market":"us","top_or_hot":-1,"title":"Sab Biotherapeutics, Inc.7月29日成交额为51.70万美元","media":"市场透视","content":"<div>\n<p>美东时间2025年7月29日，Sab Biotherapeutics, Inc.（SABS.US）成交额为51.70万美元，成交额较昨日增加4.62%，当日成交量为21.85万股。Sab Biotherapeutics, Inc.（SABS.US）于2025年7月29日跌10.47%，报2.27美元，该股过去5个交易日跌13.22%，年初至今跌40.24%，过去60日涨33.24%。|近5个交易日...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730135943a46aeb51&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sab Biotherapeutics, Inc.7月29日成交额为51.70万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSab Biotherapeutics, Inc.7月29日成交额为51.70万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-30 13:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730135943a46aeb51&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美东时间2025年7月29日，Sab Biotherapeutics, Inc.（SABS.US）成交额为51.70万美元，成交额较昨日增加4.62%，当日成交量为21.85万股。Sab Biotherapeutics, Inc.（SABS.US）于2025年7月29日跌10.47%，报2.27美元，该股过去5个交易日跌13.22%，年初至今跌40.24%，过去60日涨33.24%。|近5个交易日...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730135943a46aeb51&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730135943a46aeb51&s=b","article_id":"2555097653","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730135943a46aeb51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555097653","pubTimestamp":1753855181,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"美东时间2025年7月29日，Sab Biotherapeutics, Inc.成交额为51.70万美元，成交额较昨日增加4.62%，当日成交量为21.85万股。Sab Biotherapeutics, Inc.于2025年7月29日跌10.47%，报2.27美元，该股过去5个交易日跌13.22%，年初至今跌40.24%，过去60日涨33.24%。该公司的新型DiversitAb 平台可以利用转染色体牛快速生产大量有针对性的人类多克隆抗体，转染色体牛的基因设计是在对抗原做出反应时产生人类抗体而不是牛抗体。动物抗体已经在兔子、羊和马身上制造出来。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","SABS":"SAB Biotherapeutics, Inc."},"translate_title":"Sab Biotherapeutics, Inc. turnover of $517,000 on July 29","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SABS":0.9},"content_text":"美东时间2025年7月29日，Sab Biotherapeutics, Inc.（SABS.US）成交额为51.70万美元，成交额较昨日增加4.62%，当日成交量为21.85万股。Sab Biotherapeutics, Inc.（SABS.US）于2025年7月29日跌10.47%，报2.27美元，该股过去5个交易日跌13.22%，年初至今跌40.24%，过去60日涨33.24%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-29|51.70万|4.62%|21.85万|#|2025-07-28|49.41万|-11.67%|19.32万|#|2025-07-25|55.94万|-62.04%|21.26万|#|2025-07-24|147.36万|-6.54%|55.40万|#|2025-07-23|157.67万|-54.07%|61.71万|SAB Biotherapeutics Inc 是一家临床阶段的生物制药公司，专注于开发和商业化其专有免疫治疗平台的产品组合，以生产完全靶向的人多克隆抗体，而无需使用人血浆或血清。该公司的新型DiversitAb 平台可以利用转染色体牛（Tc Bovine）快速生产大量有针对性的人类多克隆抗体，转染色体牛的基因设计是在对抗原做出反应时产生人类抗体（免疫球蛋白 G）而不是牛抗体。动物抗体已经在兔子、羊和马身上制造出来。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555097653","isCrawlerRequest":true}